Retail pharmacy chains, e-pharmacy and the distributor layer in the UAE and Saudi Arabia: market size, the chains (Nahdi, Al Dawaa, Aster, Life, BinSina), distributors, margins and regulation, and what manufacturers and hospital groups should know.
Pharmacy retail and distribution in the GCC is concentrated and regulated: a few national chains dominate retail in Saudi Arabia (Nahdi, Al Dawaa) and the UAE (Aster, Life, BinSina, Medicina, Boots/Alliance), and a small number of licensed distributors (Pharmalink, Julphar, Gulf Drug, Al Ittihad, Cigalah, Tamer, Banaja, Bin Zagr) hold the agencies through which imported medicines reach the market. Published estimates for 2025 range from USD 8.8 bn to USD 18.9 bn; our central estimate is USD 28.0 bn, growing at about 4% to USD 38.1 bn by 2032.
Growth comes from insurance-covered prescriptions, OTC and wellness categories, chain expansion and e-pharmacy (regulated, delivery-led). Regulation sets maximum prices and margins (MOHAP, SFDA), mandates serialisation (Tatmeen, RSD) and licenses pharmacists; chains are vertically integrating into distribution and private label.
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 8.8 bn–USD 18.9 bn; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| Credence Research (2025) — UAE retail pharmacy market; Dubai 46.5%, Abu Dhabi 39.2% of | USD 8.62 bn (2024) | USD 10.40 bn (2032) | 2.38% |
| IMARC Group (2025) — Saudi Arabia pharmacy retail; organised 77%, prescribed 58%, | USD 18.9 bn (2025) | USD 30.1 bn (2034) | 5.28% (2026-2034) |
| Argaam Weekend (industry estimate) (2026-03) — Saudi pharmacy market; >9,000 outlets; Nahdi + Al Dawaa hold | USD 12-14 bn (2025) | — () | 6-8% |
| Ken Research (2025) — Saudi Arabia pharmaceutical distribution market; hospitals l | USD 8.5 bn (2025) | USD 11.5 bn (2031) | 6.75% |
| JLL (via Khaleej Times) (2026-08) — GCC pharmaceutical market (total); locally produced generics | USD 30+ bn (2025) | — () | ~7.5% annual |
| IMARC Group (2025) — GCC e-pharmacy market; use CAGR only, absolute values as sta | USD 2.7 mn (as published; likely bn-scale error) (2025) | USD 10.0 mn (as published) (2034) | 14.78% (2026-2034) |
| Consulting Wallah central estimate | USD 28.0 bn (2025) | USD 38.1 bn (2032) | ~4% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: retail pharmacy sales (prescription, OTC, wellness, medical consumables sold at retail), e-pharmacy, and the pharmaceutical wholesale/distribution layer. Excluded: hospital pharmacy purchases (in hospital reports), manufacturing. Regulation: MOHAP/DoH/DHA (UAE), SFDA and MoH (Saudi), Emirates Drug Establishment.
Shares as reported by the named sources; ranking is more reliable than the exact percentage.
| Segment | Share | Note | |
|---|---|---|---|
| Dubai | 46.5% | ||
| Abu Dhabi | 39.2% | ||
| Northern Emirates | 14% |
Source: Credence Research https://www.credenceresearch.com/report/uae-retail-pharmacy-market
| Segment | Share | Note | |
|---|---|---|---|
| Organised chains | 77% | by structure | |
| Prescribed drugs | 58% | by product | |
| Generic | 57% | by drug type | |
| Cardiovascular | 24% | by therapy area | |
| Street/mall-based | 72% | by location | |
| Northern & Central region | 32% |
Source: IMARC https://www.imarcgroup.com/saudi-arabia-pharmacy-retail-market
| Segment | Share | Note | |
|---|---|---|---|
| Nahdi | 35% | 1,100+ outlets | |
| Al Dawaa | 25% | ~900 outlets | |
| United Pharmacies (UPC) | 10% | ~500 stores + Kunooz 90-110 |
Source: Argaam Weekend https://weekend.argaam.com/91/en/saudi-pharmacy-growth
| Segment | Share | Note | |
|---|---|---|---|
| Online | 25% | ||
| Physical retail | 75% | retail revenue +7.3% YoY |
Source: AGBI https://www.agbi.com/markets/2025/07/store-expansion-drives-up-nahdi-medicals-profit
| Country / region | Figure | Year | Source |
|---|---|---|---|
| UAE retail pharmacy market | USD 8.62 bn (2024) to USD 10.40 bn (2032) | 2024 | Credence Research |
| Dubai licensed pharmacies | 1,794 (+6.8% YoY) | H1 2026 | DHA via Khaleej Times |
| Saudi pharmacy retail market | USD 18.9 bn (2025) to USD 30.1 bn (2034) | 2025 | IMARC |
| Saudi pharmacy outlets | >9,000 | 2026 | Argaam Weekend |
| Saudi pharmaceutical distribution market | USD 8.5 bn (2025) to USD 11.5 bn (2031) | 2025 | Ken Research |
| GCC pharmaceutical market | USD 30+ bn, growing ~7.5% p.a. | 2025 | JLL via Khaleej Times |
| Nahdi Medical FY2025 | Revenue SAR 10.21 bn (+8.1%); net profit SAR 830.7 mn (+1.2%) | 2025 | Decypha / Tadawul |
| Nahdi store network | 1,207 stores (Saudi + UAE), 59 opened in H1 2025 | 2025 | AGBI |
| Aster Pharmacy network | 300+ outlets, 2,025 pharmacists across UAE & GCC; 14 in Saudi (20 by Mar 2025) | 2025 | Gulf News |
| Life Pharmacy network | 400th outlet opened (UAE's largest chain) | 2023 | Khaleej Times |
Source: Sources as named; see Sources and method.
Nahdi (listed) and Al Dawaa lead; NUPCO supplies public hospitals, not retail; distributors (Cigalah, Tamer, Banaja, Bin Zagr, Salehiya) hold agencies; e-pharmacy and delivery grew post-COVID under SFDA rules.
Aster, Life, BinSina and Medicina chains expand with malls and insurer networks; distributors (Pharmalink, Gulf Drug, Al Ittihad, Julphar) control imports; Tatmeen applies at retail; online pharmacy is licensed under DHA/MOHAP.
Indian generics reach GCC retail through these distributors; Indian retail models (Apollo Pharmacy, MedPlus, Tata 1mg) are benchmarks for scale and e-pharmacy; Indian pharmacists are a large share of the GCC workforce.
| Date | Development | Source |
|---|---|---|
| 2025-01 | Aster announces Saudi JV with Al Hokair Holding to open 180+ pharmacies in five years with ~USD 250 mn investment and myAster app launch in KSA. | Gulf News |
| 2025-07 | Nahdi reports H1 2025 revenue SAR 5.1 bn (+9%), 1,207 stores and online at 25% of revenue. | AGBI |
| 2026-03 | Nahdi posts FY2025 revenue of SAR 10.21 bn (+8.1%) and net profit SAR 830.7 mn. | Decypha |
| 2026-03 | United Pharmacies acquires Kunooz (90-110 stores) for over SAR 100 mn, targeting 13% Saudi share by end-2026. | Argaam Weekend |
| 2026-08 | JLL reports GCC pharmaceutical market topped USD 30 bn in 2025 with USD 12 bn biotech investment 2020-25. | Khaleej Times |
| 2026-10 | DHA reports 1,794 licensed pharmacies in Dubai (+6.8%) in H1 2026. | Khaleej Times |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from USD 8.8 bn to USD 18.9 bn. Consulting Wallah’s central estimate is USD 28.0 bn in 2025, rising to about USD 38.1 bn by 2032.
Published CAGRs range from 2.38% to 5.28%; our central case is about 4% a year to 2032.
Nahdi Medical Company, Al Dawaa Medical Services, United Pharmacies (UPC) / Kunooz, Aster Pharmacy (Aster DM Healthcare), Life Pharmacy (Life Healthcare Group), BinSina Pharmacy, Supercare Pharmacy, Boots Pharmacy (Alshaya) among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.